ER2, a novel human anti-EGFR monoclonal antibodyinhibit tumor activity innon-small cell lung cancer models

Highlights • ER2 suppressed EGFR pathway and induced G1 arrest and apoptosis in NSCLC cells. • ER2 inhibited EGF-stimulated VEGF production. • ER2 induced anti-tumor activity in combination with cisplatin in xenograft models.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Lung cancer (Amsterdam, Netherlands) Netherlands), 2016
Hauptverfasser: Kang, Han Na, Kim, Se-Ho, Yun, Mi Ran, Kim, Hye Ryun, Lim, Sun Min, Kim, Min-Soo, Hong, Kwang-Won, Kim, Sung-Moo, Kim, Hwan, Pyo, Kyoung-Ho, Park, Hye Ji, Han, Joo Yeun, Youn, Hyun A, Chang, Ki-Hwan, Cho, Byoung Chul
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Highlights • ER2 suppressed EGFR pathway and induced G1 arrest and apoptosis in NSCLC cells. • ER2 inhibited EGF-stimulated VEGF production. • ER2 induced anti-tumor activity in combination with cisplatin in xenograft models.
ISSN:0169-5002
DOI:10.1016/j.lungcan.2016.02.013